258 related articles for article (PubMed ID: 35412314)
21. Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research.
Tabata K; Hamakawa N; Sanoh S; Terashita S; Teramura T
Eur J Drug Metab Pharmacokinet; 2009; 34(2):117-28. PubMed ID: 19645221
[TBL] [Abstract][Full Text] [Related]
22. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
Lüpfert C; Reichel A
Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
[TBL] [Abstract][Full Text] [Related]
23. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.
Sayama H; Komura H; Kogayu M; Iwaki M
J Pharm Sci; 2013 Nov; 102(11):4193-204. PubMed ID: 24018828
[TBL] [Abstract][Full Text] [Related]
24. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
[TBL] [Abstract][Full Text] [Related]
25. Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery.
Stoner CL; Cleton A; Johnson K; Oh DM; Hallak H; Brodfuehrer J; Surendran N; Han HK
Int J Pharm; 2004 Jan; 269(1):241-9. PubMed ID: 14698595
[TBL] [Abstract][Full Text] [Related]
26. Predicting drug metabolism and pharmacokinetics features of in-house compounds by a hybrid machine-learning model.
Sasahara K; Shibata M; Sasabe H; Suzuki T; Takeuchi K; Umehara K; Kashiyama E
Drug Metab Pharmacokinet; 2021 Aug; 39():100395. PubMed ID: 33991751
[TBL] [Abstract][Full Text] [Related]
27. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.
Jones HM; Mayawala K; Poulin P
AAPS J; 2013 Apr; 15(2):377-87. PubMed ID: 23269526
[TBL] [Abstract][Full Text] [Related]
28. Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug-drug interaction prediction.
Gill J; Moullet M; Martinsson A; Miljković F; Williamson B; Arends RH; Pilla Reddy V
CPT Pharmacometrics Syst Pharmacol; 2022 Dec; 11(12):1560-1568. PubMed ID: 36176050
[TBL] [Abstract][Full Text] [Related]
29. Machine Learning Prediction of the Three Main Input Parameters of a Simplified Physiologically Based Pharmacokinetic Model Subsequently Used to Generate Time-Dependent Plasma Concentration Data in Humans after Oral Doses of 212 Disparate Chemicals.
Kamiya Y; Handa K; Miura T; Ohori J; Kato A; Shimizu M; Kitajima M; Yamazaki H
Biol Pharm Bull; 2022 Jan; 45(1):124-128. PubMed ID: 34732590
[TBL] [Abstract][Full Text] [Related]
30. Application of Machine Learning Technology in the Prediction of ADME- Related Pharmacokinetic Parameters.
Wang Y; Zhan Y; Liu C; Zhan W
Curr Med Chem; 2023; 30(17):1945-1962. PubMed ID: 35993465
[TBL] [Abstract][Full Text] [Related]
31. Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds.
Zhang T; Heimbach T; Lin W; Zhang J; He H
J Pharm Sci; 2015 Sep; 104(9):2795-806. PubMed ID: 25690565
[TBL] [Abstract][Full Text] [Related]
32. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
Poulin P; Jones HM; Jones RD; Yates JW; Gibson CR; Chien JY; Ring BJ; Adkison KK; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Ku MS
J Pharm Sci; 2011 Oct; 100(10):4050-73. PubMed ID: 21523782
[TBL] [Abstract][Full Text] [Related]
33. Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.
Sinha VK; Vaarties K; De Buck SS; Fenu LA; Nijsen M; Gilissen RA; Sanderson W; Van Uytsel K; Hoeben E; Van Peer A; Mackie CE; Smit JW
Clin Pharmacokinet; 2011 May; 50(5):307-18. PubMed ID: 21456631
[TBL] [Abstract][Full Text] [Related]
34. In vivo rat PK profiling in drug discovery: new challenges.
Zonzini L; Bianchi F; Cesari N; Sartori M
Expert Opin Drug Discov; 2010 Nov; 5(11):1031-7. PubMed ID: 22827743
[TBL] [Abstract][Full Text] [Related]
35. Multi-Task ADME/PK prediction at industrial scale: leveraging large and diverse experimentaldatasets.
Walter M; Borghardt JM; Humbeck L; Skalic M
Mol Inform; 2024 Jul; ():e202400079. PubMed ID: 38973777
[TBL] [Abstract][Full Text] [Related]
36. A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery.
Li C; Liu B; Chang J; Groessl T; Zimmerman M; He YQ; Isbell J; Tuntland T
Drug Discov Today; 2013 Jan; 18(1-2):71-8. PubMed ID: 22982770
[TBL] [Abstract][Full Text] [Related]
37. Computational modeling of human oral bioavailability: what will be next?
Cabrera-Pérez MÁ; Pham-The H
Expert Opin Drug Discov; 2018 Jun; 13(6):509-521. PubMed ID: 29663836
[TBL] [Abstract][Full Text] [Related]
38. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
39. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
De Buck SS; Mackie CE
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):865-78. PubMed ID: 18028030
[TBL] [Abstract][Full Text] [Related]
40. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery.
Parrott N; Paquereau N; Coassolo P; Lavé T
J Pharm Sci; 2005 Oct; 94(10):2327-43. PubMed ID: 16136543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
